- Home
- GDEV vs XGN Comparison
GDEV vs XGN Comparison
Compare GDEV & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDEV | XGN |
|---|---|---|
| Founded | 2009 | 2002 |
| Country | Cyprus | United States |
| Employees | 589 | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.9M | 253.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GDEV | XGN |
|---|---|---|
| Price | $17.04 | $6.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 6.9K | ★ 246.3K |
| Earning Date | 11-24-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.98 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $412,018,000.00 | $63,599,000.00 |
| Revenue This Year | N/A | $22.15 |
| Revenue Next Year | $4.89 | $15.26 |
| P/E Ratio | $5.53 | ★ N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | $8.60 | $2.67 |
| 52 Week High | $42.20 | $12.23 |
Technical Indicators
Market Signals| Indicator | GDEV | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 24.04 |
| Support Level | $15.77 | $6.37 |
| Resistance Level | $17.88 | $7.29 |
| Average True Range (ATR) | 1.31 | 0.34 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 14.22 | 1.63 |
Price Performance
Historical ComparisonAbout GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.